Form 4: Twist Bioscience CEO Sells Shares to Cover Tax Obligations Following RSU Vesting
Insider Transaction Report
Twist Bioscience Corporation's CEO, Emily M. Leproust, sold 2,802 shares of common stock at $29.747 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction on May 21, 2025.
- The transaction involved the disposition of 2,802 shares of common stock at a price of $29.747 per share.
- This sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to fund tax withholding obligations associated with the vesting of Restricted Stock Units, and was not a discretionary trade by Ms. Leproust.
- Following this transaction, Ms. Leproust directly beneficially owns 649,630 shares of common stock.
- The filing also details various employee stock options held by Ms. Leproust, including options with exercise prices ranging from $5.95 to $67.85, with varying vesting schedules and expiration dates up to August 31, 2030.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a common and expected event for executives receiving equity compensation. It does not reflect a change in management's outlook or a discretionary sale of shares.
Positives
- The transaction was a non-discretionary 'sell to cover' to meet tax obligations, indicating a standard administrative process rather than a voluntary divestment of shares by the CEO.
Negatives
- No specific negative aspects are indicated by this routine tax-related transaction.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The sale of shares was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and does not represent discretionary trades by the Reporting Person.
Industry Context
This filing is a routine insider transaction report for a biotechnology company. 'Sell to cover' transactions are common in the industry when executive equity awards vest, as they are a standard mechanism for employees to meet tax obligations arising from compensation.
Comparison to Industry Standards
- The 'sell to cover' mechanism for tax withholding is a standard practice across many industries, including biotechnology, for equity compensation plans. It aligns with common corporate governance practices for managing executive stock awards and associated tax liabilities.
- The reported transaction volume of 2,802 shares is relatively small compared to the CEO's total beneficial ownership of 649,630 shares, which is typical for tax-related sales designed to cover specific withholding amounts rather than a significant divestment of holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Emily M. Leproust granted Power of Attorney to Dennis Cho, Judy Yan, and Kendra Fox to act as her attorneys-in-fact for filing Forms 3, 4, and 5 with the SEC, managing her EDGAR account, and obtaining transaction information. | 2025-05-08 | This is a standard administrative delegation of authority to ensure timely and compliant SEC filings for insider transactions, enhancing corporate governance efficiency related to Section 16 reporting. |
Stakeholder Impact
- Shareholders: The transaction is a routine tax-related sale and is unlikely to have a significant impact on shareholder perception or the company's valuation, as it is not a discretionary sale.
- Employees: The 'sell to cover' mechanism is a common practice in equity incentive plans, which may be relevant to employees with similar equity awards.
Key Dates
| Date | Description |
|---|---|
| 2016-09-01 | Vesting start date for an employee stock option with an exercise price of $5.95 (25% vested, then 1/48th monthly). |
| 2017-09-28 | Vesting start date for an employee stock option with an exercise price of $8.82 (10% vested, then 15% on 9/28/2018, then 1/48th monthly). |
| 2019-10-31 | Vesting start date for an employee stock option with an exercise price of $26.66 (20% vested, then 1/60th monthly). |
| 2020-09-01 | Grant date for performance stock options with an exercise price of $67.85. |
| 2020-10-24 | Vesting start date for an employee stock option with an exercise price of $23.33 (25% vested, then 1/48th monthly). |
| 2022-12-19 | Date performance stock options (exercise price $67.85) vested and became exercisable due to performance criteria being met. |
| 2025-05-08 | Date Power of Attorney was executed by Emily M. Leproust. |
| 2025-05-21 | Date of the reported transaction (sale of common stock). |
| 2025-05-23 | Date the Form 4 was signed by the Attorney-in-Fact. |
| 2025-09-28 | Expiration date for an employee stock option with an exercise price of $5.95. |
| 2027-09-28 | Expiration date for an employee stock option with an exercise price of $8.82. |
| 2028-11-18 | Expiration date for an employee stock option with an exercise price of $26.66. |
| 2029-10-23 | Expiration date for an employee stock option with an exercise price of $23.33. |
| 2030-08-31 | Expiration date for an employee stock option with an exercise price of $67.85. |
Keywords
Twist Bioscience, TWST, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Tax Withholding, Biotechnology, Synthetic Biology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.